Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT01864681 2018-06-20

CGMT

Phase 2 Completed

224 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

16 enrolled

Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms

NCT00509002 2017-11-24

Iressa Study in Patients With Salivary Gland Cancer

Phase 2 Completed

37 enrolled 4 charts

Head & Neck

Salivary Gland Neoplasms

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00310154 2017-05-30

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1 Completed

45 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03157310 2017-05-17

Bone Metastasis on the Survival of Gefitinib Effective Patients

Phase NA Completed

265 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00186979 2017-04-26

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Phase 1 Completed

34 enrolled

Other solid neoplasm

Solid Tumors

NCT00188617 2017-03-14

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Phase 2 Completed

35 enrolled

Thoracic

Lung Neoplasms

NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

31 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01404260 2017-01-27

ISCAN

Phase 3 Completed

219 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01203917 2017-01-02

IFUM

Phase 4 Completed

1,060 enrolled 14 charts

Thoracic

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

NCT00062062 2016-12-14

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

65 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00100945 2016-12-13

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2 Completed

70 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT00059722 2016-08-24

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Phase 2 Completed

160 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00519077 2016-07-01

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

44 enrolled 7 charts

Head & Neck

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT02040064 2016-06-09

GEFTREM

Phase 1 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00259064 2016-06-02

INSTEP

Phase 2/3 Completed

216 enrolled

Thoracic

NSCLC

NCT02148380 2016-04-20

Combination of Chemotherapy and Gefitinib as First-line Treatment

Phase NA Completed

121 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01530334 2016-02-23

ICARUS

Phase 2 Completed

61 enrolled 11 charts

Thoracic

Lung Neoplasms

Clinical Trials

FLAURA

BM

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

GOAL

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

BKM120

MK-3475-021

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

LADIE

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Third-line Treatment of Gefitinib in NSCLC Patients

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

MetAction

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

CGMT

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Iressa Study in Patients With Salivary Gland Cancer

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Bone Metastasis on the Survival of Gefitinib Effective Patients

Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

ISCAN

IFUM

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

GEFTREM

INSTEP

Combination of Chemotherapy and Gefitinib as First-line Treatment

ICARUS